2 recruiting, 1 available, 1 not yet recruiting. 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Vepugratinib: new trials by email Literature Review of Vepugratinib trials Research Report on Vepugratinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer Vepugratinib - Urinary Bladder Neoplasms, Urologic Neoplasms | Phase 2 | Not yet recruiting | Eli Lilly and Company | 161 | 2026-12-01 | 2026-10-08 |
| A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract Vepugratinib, Placebo, EV - Carcinoma, Transitional Cell, Urinary Bladder Neoplasms | Phase 3 | Recruiting | Eli Lilly and Company | 450 | 2025-12-12 | 2026-10-07 |
| FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3 Vepugratinib, Pembrolizumab, enfortumab vedotin - Urinary Bladder Neoplasms, Neoplasm Metastasis | Phase 1 | Recruiting | Eli Lilly and Company | 677 | 2023-01-12 | 2026-08-20 |
| Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors Vepugratinib - Urinary Bladder Neoplasms, Neoplasm Metastasis | Available | Eli Lilly and Company | 2026-06-30 |
Urinary Bladder Neoplasms (4) · Neoplasm Metastasis (3) · Carcinoma, Transitional Cell (2) · Urologic Neoplasms (2) · Non-Muscle Invasive Bladder Neoplasms (1) · Ureteral Neoplasms (1)
United States (3) · Australia (2) · Canada (2) · China (2) · France (2) · Germany (2) · Italy (2) · Japan (2) · Netherlands (2) · South Korea (2) · Spain (2) · United Kingdom (2) · Brazil (1) · Czechia (1) · Denmark (1)
2025 (1)